Physical and chemical stability of cisplatin infusions in PVC containers
dc.contributor.author | Sewell, GJ | |
dc.date.accessioned | 2015-10-27T16:16:54Z | |
dc.date.available | 2015-10-27T16:16:54Z | |
dc.date.issued | 2010 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/3710 | |
dc.description.abstract |
Study objectives: To determine the extended chemical and physical stability of cisplatin infusions in PVC containers at normal in-use concentrations in saline, with and without added electrolyte combinations relevant to clinical practice. Methods: Cisplatin infusions 0.1-0.4 mg/mL were prepared in normal saline, with and without magnesium sulphate and potassium chloride supplements in 500 mL PVC bags, and stored at 25°C protected from light. Chemical stability was assessed by a stability-indicating LC method. Evidence for precipitation was detected by a light-blocking particle count method for sub-visible particles, supported by visual examination. pH and weight changes were also monitored for at least 28 days. Results: Both 0.1 mg/mL and 0.4 mg/mL infusions, with or without the added electrolyte supplements, were chemically stable over 28 days at 25°C. The pH of infusions varied by no more than 0.2 units over this time, there was no visible precipitation, and no significant changes in sub-visual particulate levels or infusion weight. The study was restricted to 28 days because small, visual precipitation was evident in some infusions after 25 days. Conclusion: Cisplatin infusions at concentrations ranging from 0.1-0.4 mg/mL, in 500 mL PVC bags containing either 0.9% sodium chloride or 0.9% sodium chloride + 20 mmoL KCI + 8 mmoL MgSO₄ were physically and chemically stable for up to 28 days at 25°C, when protected from light. Extending shelf lives beyond this period is unsafe due to the potential development of precipitates. | |
dc.format.extent | 11-13 | |
dc.language.iso | en | |
dc.title | Physical and chemical stability of cisplatin infusions in PVC containers | |
dc.type | journal-article | |
dc.type | Article | |
plymouth.edition | 2010 | |
plymouth.issue | 1 | |
plymouth.volume | 4 | |
plymouth.publication-status | Published | |
plymouth.journal | European Journal of Oncology Pharmacy | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/School of Health Professions | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy MANUAL | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Health and Community | |
plymouth.organisational-group | /Plymouth/Users by role | |
dcterms.dateAccepted | 2010-01-01 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.type | Journal Article/Review |